Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.
The current price of XVIPF is $29.00 USD — it has increased by +51.44% in the past 24 hours. Watch Xvivo Perfusion AB stock price performance more closely on the chart.
What is Xvivo Perfusion AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Xvivo Perfusion AB stocks are traded under the ticker XVIPF.
What is Xvivo Perfusion AB market cap?▼
Today Xvivo Perfusion AB has the market capitalization of 913.51M
When is the next Xvivo Perfusion AB earnings date?▼
Xvivo Perfusion AB is going to release the next earnings report on July 14, 2026.
What were Xvivo Perfusion AB earnings last quarter?▼
XVIPF earnings for the last quarter are 0.12 USD per share, whereas the estimation was 0.1 USD resulting in a +21.84% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Xvivo Perfusion AB revenue for the last year?▼
Xvivo Perfusion AB revenue for the last year amounts to 236.82M USD.
What is Xvivo Perfusion AB net income for the last year?▼
XVIPF net income for the last year is 4.85M USD.
How many employees does Xvivo Perfusion AB have?▼
As of July 02, 2026, the company has 193 employees.
In which sector is Xvivo Perfusion AB located?▼
Xvivo Perfusion AB operates in the Health & Wellness sector.
When did Xvivo Perfusion AB complete a stock split?▼
Xvivo Perfusion AB has not had any recent stock splits.
Where is Xvivo Perfusion AB headquartered?▼
Xvivo Perfusion AB is headquartered in Mölndal, Sweden.